View of EVALUATION OF TREATMENT OUTCOMES OF STAGE IIIB–IV NON- SMALL CELL LUNG CANCER WITH EGFR MUTATIONS USING FIRST-GENERATION TYROSINE KINASE INHIBITORS AT CAN THO CITY IN 2020 - 2023

Return to Article Details EVALUATION OF TREATMENT OUTCOMES OF STAGE IIIB–IV NON- SMALL CELL LUNG CANCER WITH EGFR MUTATIONS USING FIRST-GENERATION TYROSINE KINASE INHIBITORS AT CAN THO CITY IN 2020 - 2023 Download Download PDF